By admin 
Two years ago, Alnylam Pharmaceuticals unveiled groundbreaking study data, demonstrating that patients suffering from a deadly heart condition, transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM), could experience extended lifespans and significantly reduced hospitalizations when treated with a novel nucleic acid-based medicine, Amvuttra (vutrisiran), developed by the company. This pivotal finding, derived from the HELIOS-B study, suggested substantial additive benefits when Amvuttra was administered alongside existing standard-of-care medications. The positive outcomes propelled Alnylam’s market valuation by billions of dollars and swiftly led to Amvuttra’s regulatory approval for ATTR-CM, cementing its position as a critical therapeutic advancement.
However, the landscape of ATTR-CM treatment has been dramatically recalibrated by new study results published in the prestigious New England Journal of Medicine and presented at a major medical meeting on Friday. These findings, stemming from the CARDIO-TTRansform trial conducted by AstraZeneca and Ionis Pharmaceuticals, revealed that a similar nucleic acid-based medication, eplontersen (marketed as Waiuna for another indication), failed to achieve comparable benefits in ATTR-CM patients. The top-line results, initially released in July, immediately triggered widespread questions among medical professionals and investors alike regarding the efficacy of such "silencing" drugs in combination with standard treatments and, by extension, the precise impact of Alnylam’s Amvuttra.
Understanding Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
To fully grasp the significance of these developments, it is essential to understand ATTR-CM. Transthyretin amyloidosis (ATTR) is a progressive, debilitating, and often fatal disease caused by the misfolding of the transthyretin (TTR) protein. Normally, TTR acts as a transport protein for thyroid hormones and vitamin A. However, due to genetic mutations (hereditary ATTR, or hATTR) or age-related instability (wild-type ATTR, or wtATTR), the TTR protein can misfold, aggregate, and deposit as insoluble amyloid fibrils in various tissues and organs. When these amyloid deposits primarily accumulate in the heart, they lead to ATTR-CM, causing the heart muscle to stiffen and thicken, impairing its ability to pump blood effectively. This leads to progressive heart failure, arrhythmias, and a host of other debilitating symptoms, ultimately resulting in a poor prognosis if left untreated. Historically, treatment options for ATTR-CM were limited to supportive care and organ transplantation in select cases, with a median survival of only 2 to 5 years after diagnosis, underscoring a significant unmet medical need.
The Evolving Treatment Paradigm: Stabilizers vs. Silencers
The therapeutic landscape for ATTR-CM has seen remarkable evolution over the past decade, driven by a deeper understanding of the disease’s molecular mechanisms. Prior to the advent of nucleic acid-based therapies, the primary approach centered on "stabilizing" the TTR protein. Medications like Pfizer’s Vyndamax (tafamidis) and BridgeBio’s Attruby (acoramidis) work by binding to the TTR protein, preventing its dissociation into monomers and subsequent misfolding. Tafamidis, approved in 2019, was a landmark treatment, demonstrating improved survival and reduced cardiovascular-related hospitalizations, establishing itself as the initial standard of care for ATTR-CM.
A newer class of therapies emerged with a different mechanism: "silencing" or gene suppression. These nucleic acid-based medicines, such as RNA interference (RNAi) drugs or antisense oligonucleotides (ASOs), target the messenger RNA (mRNA) responsible for producing the TTR protein. By degrading this mRNA, they effectively reduce the production of TTR protein in the liver, thereby limiting the supply of misfolding proteins available to form amyloid deposits. Alnylam’s Amvuttra (vutrisiran) and Ionis/AstraZeneca’s eplontersen (Waiuna) fall into this category.
Alnylam’s HELIOS-B Study: A Precedent of Success
In 2022, Alnylam Pharmaceuticals unveiled the full results of its Phase 3 HELIOS-B study, evaluating Amvuttra in patients with ATTR-CM. The study enrolled 655 patients, with 53% receiving concomitant TTR stabilizers, primarily tafamidis. The trial demonstrated a statistically significant reduction in the composite endpoint of all-cause mortality and recurrent cardiovascular events compared to placebo. Specifically, Amvuttra reduced all-cause mortality by 30% and cardiovascular events by 40% over an 18-month period. These results were widely celebrated as a major breakthrough, not only extending the lives of patients but also significantly improving their quality of life by reducing hospitalizations. The data strongly suggested that Amvuttra offered additive benefits when used on top of existing stabilizer medications, leading to its rapid approval by regulatory bodies and a substantial increase in Alnylam’s market capitalization. Commercially, Amvuttra quickly became a blockbuster, recording $1.9 billion in revenue in the first half of 2026, accounting for 86% of Alnylam’s total revenue, underscoring its market dominance in the ATTR space.
Eplontersen’s CARDIO-TTRansform: A Challenging Outcome
Against this backdrop of Alnylam’s success, the results from the CARDIO-TTRansform study for eplontersen present a stark contrast. Eplontersen, an antisense oligonucleotide, is already approved under the brand name Waiuna for hereditary ATTR amyloidosis affecting the nerves (hATTR-PN), a rarer form of the disease. AstraZeneca and Ionis had high hopes of expanding its label to include the larger ATTR-CM population, initiating the ambitious CARDIO-TTRansform study.
The CARDIO-TTRansform trial was a large-scale, global, randomized, double-blind, placebo-controlled study that enrolled more than 1,400 volunteers with ATTR-CM, all of whom were already receiving standard-of-care medications. Participants were randomized to receive either eplontersen or a placebo. The primary endpoint was a composite of all-cause mortality and recurrent cardiovascular events (e.g., cardiovascular death, heart failure hospitalization). After a median follow-up of 140 weeks (approximately 2.7 years), investigators found no statistically significant reduction in the risk of these events in the eplontersen group compared to placebo. Detailed data released on Friday revealed that 29% of patients in the eplontersen arm experienced such events, compared to 32% in the placebo group – a difference that fell short of statistical significance.
Immediate Market and Expert Reactions
The top-line results, first announced in July, sent ripples through the pharmaceutical market. AstraZeneca and Ionis’s stock prices experienced immediate downturns, with further dips of approximately 1% and 2%, respectively, following the detailed data release. Alnylam, despite its earlier success, also saw its shares fall by as much as 5% in morning trading on Friday, and a more significant approximately 30% drop since AstraZeneca and Ionis’s initial July announcement, reflecting broader investor concern about the "silencer" class of drugs in ATTR-CM.
Analysts were quick to weigh in. Michael Leuchten, an analyst at Jefferies covering AstraZeneca, articulated a key concern: "The negative outcome raises the possibility that the incremental benefit of combining a silencer with a [stabilizer] is smaller than previously assumed as seen in HELIOS-B, rather than the study having been designed poorly." This statement highlights the core dilemma: was the trial inherently flawed, or does it genuinely expose limitations in the combined therapeutic approach? Stifel analyst Paul Matteis, who covers Ionis, was more direct regarding eplontersen’s future in ATTR-CM, stating, "This result makes it hard for us to see a path towards filing/approval."
Unpacking the Discrepancy: Potential Explanations
The New England Journal of Medicine publication provided several insights into why eplontersen might have fallen short, offering a crucial context for understanding the difference between the CARDIO-TTRansform and HELIOS-B outcomes.
-
Evolving Standard of Care: A significant factor highlighted by the investigators was the dynamic nature of heart failure management during the trial period. They noted an "increasing" use of TTR stabilizers (such as tafamidis) and other advanced heart failure therapies throughout the CARDIO-TTRansform study. This evolution meant that patients in the placebo arm were already receiving highly effective treatments, making it considerably more challenging for eplontersen to demonstrate an additional, statistically significant benefit. In contrast, the HELIOS-B study for Amvuttra, while also including patients on stabilizers, had a lower proportion (53% vs. 81% in CARDIO-TTRansform) and was conducted in an earlier treatment era. This difference in baseline standard of care could have created a higher bar for CARDIO-TTRansform to clear.
-
Broader Inclusion Criteria and Disease Spectrum: The CARDIO-TTRansform trial utilized "broad inclusion criteria," enrolling patients across the full spectrum of ATTR-CM disease severity. The investigators suggested that "in such patients, treatments that reduce new amyloid production, such as eplontersen, may be less likely to be beneficial, as was observed in this trial." For patients with more advanced disease, where significant amyloid deposits have already accumulated and caused irreversible damage, simply reducing the production of new TTR protein might not be sufficient to significantly alter the course of the disease or improve clinical outcomes. In these cases, therapies that aim to remove existing amyloid deposits or stabilize the heart might be more impactful.
-
Additive Benefit Reassessment: The results strongly compel a re-evaluation of the "additive benefit" hypothesis for combining TTR silencers with TTR stabilizers. While the HELIOS-B data suggested such a benefit, the CARDIO-TTRansform results imply that this incremental gain might be smaller or non-existent when stabilizers are already highly effective and widely used. This raises fundamental questions about the optimal timing and combination strategies for these different classes of ATTR-CM drugs.
Implications for Alnylam and the Future of ATTR-CM Therapy
Despite the setback for eplontersen, the commercial outlook for Alnylam’s Amvuttra may not be significantly altered, according to Stifel analyst Paul Matteis. He noted that Amvuttra’s use in combination with stabilizers is "fairly minimal," with the "primary driver of growth for [Alnylam] is further penetrating the monotherapy population." This suggests that Amvuttra’s core market strength lies in its use as a standalone therapy or in patient segments where stabilizers are not yet widely adopted or tolerated.
The bigger question for Alnylam, however, revolves around its next-generation product for TTR amyloidosis, nucresiran. Nucresiran is currently in pivotal trials, and its study design allows for the concomitant use of stabilizers and other heart failure medications. Investors fear that this design could lead to a similar negative outcome as seen with eplontersen if the incremental benefit in a combination setting proves to be elusive. Matteis suggested that Alnylam might need to "tweak nucresiran’s study design to heighten its chances of success." He outlined "multiple potential pivots," such as "biasing further enrollment towards monotherapy" or making nucresiran monotherapy’s impact the study’s "primary outcome." Matteis concluded, "The fact that the CARDIO-TTransform data are so negative for the combo (they are unequivocal) could further embolden [Alnylam] to make changes sooner." This emphasizes the immediate pressure on Alnylam to adapt its clinical strategy in light of the new data.
Emerging Therapeutic Strategies: Beyond Stabilizers and Silencers
The CARDIO-TTRansform results also underscore the need for continued innovation in ATTR-CM treatment, particularly for patients with advanced disease or those already on optimal stabilizing therapy. A new type of drug, known as a transthyretin "depleter," is emerging in clinical trials and may offer a different approach. These drugs, being developed by companies like AstraZeneca, Novo Nordisk, and the startup Attralus, are designed to bind to and actively remove existing amyloid deposits, rather than just preventing new ones from forming. If successful, depleters could address a critical unmet need, especially for patients where the burden of existing amyloid is already high.
Furthermore, the results call for a more nuanced approach to personalized medicine in ATTR-CM. Future treatment algorithms may need to consider disease stage, genetic subtype, and the presence of existing amyloid burden more carefully when determining the optimal therapeutic strategy, whether it involves monotherapy, combination therapy, or sequential treatment approaches. The ATTR-CM field, while having made tremendous strides, remains a dynamic and challenging area, now facing a period of critical re-evaluation of established paradigms. The eplontersen outcome serves as a powerful reminder that even similar mechanisms of action can yield different clinical results depending on study design, patient population, and the ever-evolving standard of care.
